Evidence map›Paper›PMID 40841506›Full record

ArticleClinical & translational oncology : official publication of the Federation of Spanish Oncology Societies and of the National Cancer Institute of Mexico2026

Poor efficacy of anti PD-1 antibody based immunotherapy in patients with acral melanoma: results from the Spanish Melanoma Group (GEM) registry.

Maria Gonzalez-Cao, Miguel-Ángel Berciano-Guerrero, Eva Muñoz-Couselo, José Luis Manzano, Pablo Cerezuela-Fuentes, Guillermo Crespo, Ainara Soria, Pablo Ayala de Miguel, Lourdes Gutiérrez Sanz, Carlos Aguado de la Rosa and 13 more

Abstract read
PubMed Publisher
In one paragraph

Article in Clinical & translational oncology : official publication of the Federation of Spanish Oncology Societies and of the National Cancer Institute of Mexico, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 2 papers.

0numbers the graph read from it
0cells of the map it votes in
2citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

2 citing papers in PubMed.

  1. Article
  2. Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

23 authors.

Maria Gonzalez-CaoMedical Oncology Department, Instituto Oncologico Dr Rosell, Dexeus University Hospital, Carrer de Sabino Arana, 5, Les Corts, 08028, Barcelona, Spain. mgonzalezcao@oncorosell.com.ORCID http://orcid.org/0000-0003-3791-540X
Miguel-Ángel Berciano-GuerreroMedical Oncology Department, Hospital Regional Universitario de Málaga (HRU), Instituto de Investigaciones Biomédicas de Málaga (IBIMA), Málaga, Spain.
Eva Muñoz-CouseloMedical Oncology Department. Hospital, Institute of Oncology (VHIO), Universitari Vall d Hebron y Vall d Hebron, Barcelona, Spain.
José Luis ManzanoMedical Oncology Department, Instituto Catalán de Oncología, ICO-Badalona, H. Germans Triasi Pujol, Badalona, Spain.
Pablo Cerezuela-FuentesMedical Oncology Department, Hospital Clínico Universitario Virgen de La Arrixaca, Instituto Murciano de Investigación Biosanitaria (IMIB)-Arrixaca, Ciudad de Murcia, Spain.
Guillermo CrespoMedical Oncology Department, Hospital Universitario de Burgos, Burgos, Spain.
Ainara SoriaMedical Oncology Department, Hospital Universitario Ramón y Cajal, Madrid, Spain.
Pablo Ayala de MiguelMedical Oncology Department, Hospital Universitario San Pedro de Alcántara, Cáceres, Spain.
Lourdes Gutiérrez SanzMedical Oncology Department, Hospital Universitario Puerta de Hierro, Madrid, Spain.
Carlos Aguado de la RosaMedical Oncology Department, Hospital Universitario Clínico San Carlos, Madrid, Spain.
Almudena García CastañoMedical Oncology Department, Hospital Universitario Marqués de Valdecilla, Santander, Spain.
Teresa PuértolasMedical Oncology Department, Hospital Universitario Miguel Servet, Saragossa, Spain.
Enrique EspinosaMedical Oncology Department, Hospital Universitario La Paz, CIBERONC, Madrid, Spain.
Javier MedinaMedical Oncology Department, Hospital Universitario Toledo, Toledo, Spain.
Lorena BellidoMedical Oncology Department, Complejo Asistencial Universitario de Salamanca, Salamanca, Spain.
Alfonso BerrocalMedical Oncology Department, Hospital General Universitario Valencia, Valencia, Spain.
Margarita MajemMedical Oncology Department, Hospital de la Santa Creu i Sant Pau, Barcelona, Spain.
Rafael López CastroMedical Oncology Department, Hospital Clínico Universitario de Valladolid, Valladolid, Spain.
Luis Antonio FernandezMedical Oncology Department, Parc Tauli Hospital Universitari, Barcelona, Spain.
Francisco GarciaMedical Oncology Department, Complejo Universitario Pontevedra, Pontevedra, Spain.
Maria Rodriguez de la BorbollaMedical Oncology Department, Hospital Universitario de Valme, Sevilla, Spain.
Salvador Martín AlgarraMedical Oncology Department, Clínica Universidad de Navarra, Pamplona, Spain.
Iván Márquez-RodasMedical Oncology Department, Hospital General Universitario Gregorio Marañón, Madrid, Spain.

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

backgroundAcral melanoma (AM) is uncommon in non-Asian race. Limited data exist in non-Asian population.

objectiveTo analyze the activity of immunotherapy in patients diagnosed with AM in Spain.

methodsWe analyzed clinical outcomes of AM in the nationwide Spanish Melanoma Group Registry.

results69 AM (17 stage III; 52 stage IV) and 724 cutaneous melanoma (CM) (190 stage III; 534 stage IV), predominantly non-Hispanic white. Regarding stage IV, AM patients were older (median 73.6 vs. 66.6 years, p = 0.001) and less often BRAF mutant (9.6% vs. 60.7%, p = 0.0001). First line immunotherapy (49 AM; 316 CM), response rate was 15.0% vs 39.1% (p = 0.0033), median progression free survival was 5.5 (95% CI 3.97-8.23) vs 15.3 months (95% CI 8.97- 26.3) (p = 0.001) and median OS was 17.3 (95% CI 13.32-39.97) versus 43.0 months (95% CI 30.81, NR) (p = 0.007), for AM and CM, respectively. Stage III AM were deeper (T4b in 52.9% vs. 25.3%, p = 0.02). In adjuvant anti PD-1-treated patients (14 AM; 156 CM) median RFS was 10.23 months (95% CI 6.0-NR) in AM versus NR (54.5-NR) in CM (p = 0.017) and 5 year OS was 36.1% vs. 75.8% (p = 0.034).

conclusionsOur data confirms a poor outcome of AM in the Spanish population.

Indexed as

Immune Checkpoint InhibitorsImmunotherapyMelanomaProgrammed Cell Death 1 ReceptorSkin NeoplasmsAdultAgedAged, 80 and overCutaneous Malignant MelanomaFemaleHumansMaleMiddle AgedProgression-Free SurvivalRegistriesSpainImmune Checkpoint InhibitorsPDCD1 protein, humanProgrammed Cell Death 1 ReceptorAcral melanomaAnti PD-1 AbReal world data

Identifiers

PMID40841506

What OpenQuestion holds

Textmetadata
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.